Fatty acid synthase expression in Barrett's esophagus: Implications for carcinogenesis

Journal of Clinical Gastroenterology

Volumn 45, Issue 8, 2011, Pages 665-672

  Ishimura, Norihisa ^a   Amano, Yuji ^b   Sanchez Siles, Alvaro Adolfo ^a   Fukuhara, Hiroyuki ^a   Takahashi, Yoshiko ^b   Uno, Goichi ^a   Tamagawa, Yuji ^a   Mishima, Yuko ^a   Yuki, Takafumi ^b   Ishihara, Shunji ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b SHIMANE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Barrett's esophagus; carcinogenesis; fatty acid synthase

Indexed keywords

BILE ACID; CYCLINE; CYCLOOXYGENASE 2; FATTY ACID SYNTHASE; LANSOPRAZOLE; MESSENGER RNA; MUCIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; RABEPRAZOLE;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL FEATURE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GOBLET CELL; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METAPLASIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

4-BUTYROLACTONE; ADENOCARCINOMA; AGED; ANTIGENS, CD34; APOPTOSIS; BARRETT ESOPHAGUS; BILE ACIDS AND SALTS; BIOPSY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHI-SQUARE DISTRIBUTION; CYCLOOXYGENASE 2; DISEASE PROGRESSION; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FATTY ACID SYNTHETASE COMPLEX, TYPE I; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS;

EID: 80052027214     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318207f240     Document Type: Article

References (76)

1. Cameron AJ, Zinsmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population- based clinical and autopsy findings. Gastroenterology. 1990;99:918-922. (Pubitemid 20338445)
2. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993;104:510-513. (Pubitemid 23033424)
3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146. (Pubitemid 40277094)
4. Amano Y, Kushiyama Y, Yuki T, et al. Prevalence of and risk factors for Barrett's esophagus with intestinal predominant mucin phenotype. Scand J Gastroenterol. 2006;41:873-879. (Pubitemid 43995461)
5. Kim JY, Kim YS, Jung MK, et al. Prevalence of Barrett's esophagus in Korea. J Gastroenterol Hepatol. 2005;20:633-636.
6. Zhang J, Chen XL, Wang KM, et al. Barrett's esophagus and its correlation with gastroesophageal reflux in Chinese. World J Gastroenterol. 2004;10:1065-1068. (Pubitemid 38461396)
7. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92: 212-215. (Pubitemid 27076463)
8. Schnell TG, Sontag SJ, Chejfec G. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus. Dig Dis Sci. 1992;37:137-143.
9. Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol. 1997;92:2012-2016. (Pubitemid 27476240)
10. Okita K, Amano Y, Takahashi Y, et al. Barrett's esophagus in Japanese patients: its prevalence, form, and elongation. J Gastroenterol. 2008;43:928-934.
11. Amano Y, Kinoshita Y. Barrett's esophagus: perspectives on its diagnosis and management in Asian populations. Gastroenterol Hepatol. 2008;4:45-53. (Pubitemid 351293788)
12. Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg. 2002;6:29-35.
13. Amano Y, Ishihara S, Kushiyama Y, et al. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage. Aliment Pharmacol Ther. 2004;20:793-802. (Pubitemid 39319235)
14. Moriyama N, Amano Y, Mishima Y, et al. What is the clinical significance of stromal angiogenesis in Barrett's esophagus? J Gastroenterol Hepatol. 2008;23(suppl 2):S210-S215.
15. Goldrick RB, Galton DJ. Fatty acid synthesis de novo in human adipose tissue. Clin Sci Mol Med. 1974;46:469-479.
16. Jayakumar A, Tai MH, Huang WY, et al. Human fatty acid synthase: properties and molecular cloning. Proc Natl Acad Sci U S A. 1995;92:8695-8699.
17. Paulauskis JD, Sul HS. Hormonal regulation of mouse fatty acid synthase gene transcription in liver. J Biol Chem. 1989; 264:574-577. (Pubitemid 19027644)
18. Hillgartner FB, Salati LM, Goodridge AG. Physiological and molecular mechanisms involved in nutritional regulation of fatty acid synthesis. Physiol Rev. 1995;75:47-76.
19. Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res. 2003;42:289-317. (Pubitemid 36411688)
20. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002;98:19-22. (Pubitemid 34113412)
21. Nakamura I, Kimijima I, Zhang GJ, et al. Fatty acid synthase expression in Japanese breast carcinoma patients. Int J Mol Med. 1999;4:381-387.
22. Nemoto T, Terashima S, Kogure M, et al. Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma. Pathobiology. 2001;69:297-303. (Pubitemid 36160134)
23. Kusakabe T, Nashimoto A, Honma K, et al. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology. 2002;40:71-79. (Pubitemid 34107384)
24. Ogino S, Kawasaki T, Ogawa A, et al. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol. 2007;38:842-849. (Pubitemid 46726510)
25. Crispino P, Alo PL, Rivera M, et al. Evaluation of fatty acid synthase expression in oesophageal mucosa of patients with oesophagitis, Barrett's oesophagus and adenocarcinoma. J Cancer Res Clin Oncol. 2009;135:1533-1541.
26. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:1028-1032.
27. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103:788-797. (Pubitemid 351406009)
28. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998; 33:1023-1029. (Pubitemid 28505643)
29. Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia. Aliment Pharmacol Ther. 2004;20(suppl 5):40-47. (Pubitemid 39424907)
30. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C and M criteria. Gastroenterology. 2006;131:1392-1399. (Pubitemid 44708937)
31. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172-180. (Pubitemid 29333764)
32. Amano K, Adachi K, Katsube T, et al. Role of hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J Gastroenterol Hepatol. 2001;16:132-136. (Pubitemid 32226183)
33. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87-97.
34. Amano Y, Kushiyama Y, Ishihara S, et al. Crystal violet chromoendoscopy with mucosal pit pattern diagnosis is useful for surveillance of short-segment Barrett's esophagus. Am J Gastroenterol. 2005;100:21-26. (Pubitemid 41623264)
35. Amano Y, Kushiyama Y, Yuki T, et al. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy. J Gastroenterol Hepatol. 2007;22:901-917.
36. Yuki T, Amano Y, Kushiyama Y, et al. Evaluation of modified crystal violet chromoendoscopy procedure using new mucosal pit pattern classification for detection of Barrett's dysplastic lesions. Dig Liver Dis. 2006;38:296-300. (Pubitemid 44356201)
37. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
38. Soldes OS, Kuick RD, Thompson IA II, et al. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br J Cancer. 1999;79: 595-603.
39. Dvorak K, Payne CM, Chavarria M, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut. 2007;56:763-771. (Pubitemid 46854189)
40. Kauer WK, Peters JH, DeMeester TR, et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery. 1997;122: 874-881. (Pubitemid 27495927)
41. Nehra D, Howell P, Williams CP, et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44:598-602. (Pubitemid 29195903)
42. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4:50-54.
43. Orita H, Coulter J, Tully E, et al. High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy. Cancer Biol Ther. 2010;10:549-554.
44. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7: 763-777. (Pubitemid 47469806)
45. Alo PL, Visca P, Trombetta G, et al. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori. 1999;85:35-40. (Pubitemid 29196243)
46. Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 1995;45:81-86.
47. Rashid A, Pizer ES, Moga M, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol. 1997;150:201-208. (Pubitemid 27027110)
48. Visca P, Alo PL, Del Nonno F, et al. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin Cancer Res. 1999;5:4111-4118. (Pubitemid 30013793)
49. Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX- 2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol. 2002;283:G327-G334. (Pubitemid 34791298)
50. Song S, Guha S, Liu K, et al. COX-2 induction by unconjugated bile acids involves reactive oxygen speciesmediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2007;56:1512-1521. (Pubitemid 350033188)
51. Lu S, Archer MC. Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1. Exp Biol Med (Maywood). 2007;232:643-653. (Pubitemid 46683390)
52. Accioly MT, Pacheco P, Maya-Monteiro CM, et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res. 2008;68:1732-1740. (Pubitemid 351416558)
53. Friedenberg FK, Xanthopoulos M, Foster GD, et al. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol. 2008;103:2111-2122.
54. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008;53: 2307-2312.
55. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638. (Pubitemid 36459468)
56. Murphy TK, Calle EE, Rodriguez C, et al. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol. 2000;152:847-854.
57. Diraison F, Dusserre E, Vidal H, et al. Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am J Physiol Endocrinol Metab. 2002;282:E46-E51. (Pubitemid 34654105)
58. Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000;288:2379-2381. (Pubitemid 30448165)
59. Mobbs CV, Makimura H. Block the FAS, lose the fat. Nat Med. 2002;8:335-336. (Pubitemid 34407025)
60. Mayas MD, Ortega FJ, Macias-Gonzalez M, et al. Inverse relation between FASN expression in human adipose tissue and the insulin resistance level. Nutr Metab (Lond). 2010;7:3.
61. Fernandez-Real JM, Menendez JA, Moreno-Navarrete JM, et al. Extracellular Fatty Acid synthase: a possible surrogate biomarker of insulin resistance. Diabetes. 2010;59:1506-1511.
62. Menendez JA, Vazquez-Martin A, Ortega FJ, et al. Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem. 2009;55:425-438.
63. Vazquez-Martin A, Colomer R, Brunet J, et al. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 2008;41:59-85. (Pubitemid 351147647)
64. Weng MS, Ho CT, Ho YS, et al. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling. Toxicol Appl Pharmacol. 2007;218:107-118.
65. Furuta E, Pai SK, Zhan R, et al. Fatty acid synthase gene is upregulated by hypoxia via activation of AKT and sterol regulatory element binding protein-1. Cancer Res. 2008;68:1003-1011. (Pubitemid 351278386)
66. Menendez JA, Decker JP, Lupu R. In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J Cell Biochem. 2005;94:1-4. (Pubitemid 41420319)
67. Matsukuma KE, Bennett MK, Huang J, et al. Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase. J Lipid Res. 2006;47: 2754-2761. (Pubitemid 44936088)
68. Capello A, Moons LM, Van de Winkel A, et al. Bile acidstimulated expression of the farnesoid X receptor enhances the immune response in Barrett's esophagus. Am J Gastroenterol. 2008;103:1510-1516. (Pubitemid 351813939)
69. Kridel SJ, Lowther WT, Pemble CW Jr. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Investig Drugs. 2007;16:1817-1829. (Pubitemid 350187394)
70. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006;66:5977-5980.
71. Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070-2075. (Pubitemid 38339455)
72. Wang HQ, Altomare DA, Skele KL, et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene. 2005;24: 3574-3582. (Pubitemid 40756227)
73. Gao Y, Lin LP, Zhu CH, et al. Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther. 2006;5:978-985.
74. Li JN, Gorospe M, Chrest FJ, et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 2001;61:1493-1499. (Pubitemid 34292578)
75. Thupari JN, Landree LE, Ronnett GV, et al. C75 increases peripheral energy utilization and fatty acid oxidation in dietinduced obesity. Proc Natl Acad Sci U S A. 2002;99:9498-9502. (Pubitemid 34764642)
76. Puig T, Turrado C, Benhamu B, et al. Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res. 2009;15:7608-7615.